Robert Michael will replace former CEO Richard Gonzalez, marking the official end to Gonzalez’s long reign at the pharma ...

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.

AbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0824 ET – AbbVie raises its long-term sales outlook for ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE ... The oncology sector covers the entire cancer care process, from diagnosis to treatment. Pharmaceutical and biotech ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” ...

AbbVie and Neomorph are forming a partnership ... team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases." The acquisition deal ...

AbbVie is recognized as a leading drugmaker with an extensive portfolio of therapeutics in fields such as immunology, oncology, neuroscience, and eye care. Additionally, the company commercializes ...